Sattva Neelapu, MD

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.